These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 7528296

  • 21. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
    Chiu WC, Kedem J, Weiss HR, Tse J, Cheinberg BV, Scholz PM.
    Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
    [Abstract] [Full Text] [Related]

  • 22. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
    Bethke T, Eschenhagen T, Klimkiewicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Meyer W, Neumann J, Rosswag S.
    Arzneimittelforschung; 1992 Apr; 42(4):437-45. PubMed ID: 1386515
    [Abstract] [Full Text] [Related]

  • 23. Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
    Van de Water A, Xhonneux R, Reneman RS, Janssen PA.
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):18-24. PubMed ID: 1383627
    [Abstract] [Full Text] [Related]

  • 24. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
    Sawanishi H, Suzuki H, Yamamoto S, Waki Y, Kasugai S, Ohya K, Suzuki N, Miyamoto K, Takagi K.
    J Med Chem; 1997 Sep 26; 40(20):3248-53. PubMed ID: 9379444
    [Abstract] [Full Text] [Related]

  • 25. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
    Heber D, Heers C, Ravens U.
    Pharmazie; 1993 Jul 26; 48(7):537-41. PubMed ID: 7692456
    [Abstract] [Full Text] [Related]

  • 26. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
    Picq M, Dubois M, Grynberg A, Lagarde M, Prigent AF.
    J Mol Cell Cardiol; 1996 Oct 26; 28(10):2151-61. PubMed ID: 8930810
    [Abstract] [Full Text] [Related]

  • 27. Comparisons of the depressor, inotropic and renal effects of milrinone and CI-930 to different pure vasodilators and diuretics in conscious instrumented dogs.
    Lee KC, Clas DM, Gorczyca WP, Silver PJ, Ezrin AM.
    Drugs Exp Clin Res; 1991 Oct 26; 17(7):323-36. PubMed ID: 1686584
    [Abstract] [Full Text] [Related]

  • 28. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
    Nicholson CD, Shahid M, Bruin J, Barron E, Spiers I, de Boer J, van Amsterdam RG, Zaagsma J, Kelly JJ, Dent G.
    J Pharmacol Exp Ther; 1995 Aug 26; 274(2):678-87. PubMed ID: 7636728
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.
    Sato N, Asai K, Okumura S, Takagi G, Shannon RP, Fujita-Yamaguchi Y, Ishikawa Y, Vatner SF, Vatner DE.
    Am J Physiol; 1999 May 26; 276(5):H1699-705. PubMed ID: 10330256
    [Abstract] [Full Text] [Related]

  • 30. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.
    Heaslip RJ, Lombardo LJ, Golankiewicz JM, Ilsemann BA, Evans DY, Sickels BD, Mudrick JK, Bagli J, Weichman BM.
    J Pharmacol Exp Ther; 1994 Feb 26; 268(2):888-96. PubMed ID: 8114002
    [Abstract] [Full Text] [Related]

  • 31. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 32. Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats.
    Lee KC, Silver PJ, Bode DC, Gherezghiher T.
    Methods Find Exp Clin Pharmacol; 1993 Oct 15; 15(8):527-34. PubMed ID: 8309316
    [Abstract] [Full Text] [Related]

  • 33. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
    Barnette MS, Manning CD, Price WJ, Barone FC.
    J Pharmacol Exp Ther; 1993 Feb 15; 264(2):801-12. PubMed ID: 7679736
    [Abstract] [Full Text] [Related]

  • 34. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
    Rose RJ, Liu H, Palmer D, Maurice DH.
    Br J Pharmacol; 1997 Sep 15; 122(2):233-40. PubMed ID: 9313930
    [Abstract] [Full Text] [Related]

  • 35. CDP840: a novel inhibitor of PDE-4.
    Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ.
    Cell Biochem Biophys; 1998 Sep 15; 29(1-2):113-32. PubMed ID: 9631241
    [Abstract] [Full Text] [Related]

  • 36. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.
    Raeburn D, Karlsson JA.
    J Pharmacol Exp Ther; 1993 Dec 15; 267(3):1147-52. PubMed ID: 8263775
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.
    Silver PJ, Pagani ED, Dundore RL, de Garavilla L, Bode DC, Bacon ER.
    Eur J Pharmacol; 1998 May 22; 349(2-3):263-8. PubMed ID: 9671106
    [Abstract] [Full Text] [Related]

  • 38. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
    Sato N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():43-8. PubMed ID: 17571364
    [No Abstract] [Full Text] [Related]

  • 39. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
    Harrison SA, Chang ML, Beavo JA.
    Circulation; 1986 Mar 28; 73(3 Pt 2):III109-16. PubMed ID: 3002661
    [Abstract] [Full Text] [Related]

  • 40. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
    Murray KJ, Eden RJ, England PJ, Dolan J, Grimsditch DC, Stutchbury CA, Patel B, Reeves ML, Worby A, Torphy TJ.
    Agents Actions Suppl; 1991 Mar 28; 34():27-46. PubMed ID: 1665307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.